DR info

臨床試験数 : 22 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 14

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Allo-hMSCs
   Longeveron Inc.
      2015   Phase 1   NCT02398604   United States;
Ambrisentan
   Kevin Hill
      2015   Phase 2   NCT02080637   United States;
Autologous (self) mononuclear cells derived from umbilical cord blood
   Timothy J Nelson, MD, PhD
      2019   Phase 2   NCT03779711   United States;
Autologous Human Placental Cord Blood Mononuclear Cells
   Murdoch Childrens Research Institute
      2018   Phase 1   NCT03431480   Australia;
Autologous Umbilical Cord Blood
   Michael Cotten
      2011   Phase 1   NCT01445041   United States;
Autologous cell-based delivery
   Timothy J Nelson, MD, PhD
      2013   Phase 1   NCT01883076   United States;
Bosentan
   Rigshospitalet, Denmark
      2011   Phase 2   NCT01292551   Denmark;Sweden;
C-kit+ cells
   University of Miami
      2019   Phase 1   NCT03406884   United States;
Curosurf
   University of Michigan
      2020   Phase 1   NCT04181255   United States;
Erythropoetin
   Baylor College of Medicine
      2006   Phase 1/Phase 2   NCT00513240   United States;
Lomecel-B medicinal signaling cells
   Ann & Robert H Lurie Children's Hospital of Chicago
      2021   Phase 2   NCT04925024   United States;
Longeveron Mesenchymal Stem Cells
   Longeveron Inc.
      2018   Phase 1/Phase 2   NCT03525418   United States;
METHYLPREDNISOLONE SODIUM SUCCINATE
   Pertti Suominen
      2009   -   EUCTR2008-007413-76-FI   Finland;
MPC
   Boston Children's Hospital
      2017   Phase 1/Phase 2   NCT03079401   United States;
Maternal Hyperoxygenation
   The Hospital for Sick Children
      2018   Phase 1/Phase 2   NCT03136835   Canada;
Maternal hyperoxygenation
   Beijing Anzhen Hospital
      2016   -   NCT03147014   China;
Metyyliprednisoloninatriumsuksinaatti
   Pertti Suominen
      2009   -   EUCTR2008-007413-76-FI   Finland;
Nitrogen
   Institutional Review Board of Kagoshima University
      2015   -   JPRN-UMIN000017311   Japan;
Normal saline
   Baylor College of Medicine
      2006   Phase 1/Phase 2   NCT00513240   United States;
Oxandrolone
   HealthCore-NERI
      2019   Phase 1/Phase 2   NCT04090697   Canada;United States;
Rexlemestrocel-L
   Boston Children's Hospital
      2017   Phase 1/Phase 2   NCT03079401   United States;
Sham
   University of Michigan
      2020   Phase 1   NCT04181255   United States;
Sildenafil
   Children's Hospital of Philadelphia
      2007   Phase 2   NCT00507819   United States;
Stage II Surgical repair
   Timothy J Nelson, MD, PhD
      2019   Phase 2   NCT03779711   United States;
Tracleer
   Lars Søndergaard
      2010   -   EUCTR2010-022389-28-DK   Denmark;
Vitamin C
   University of Michigan
      2009   -   NCT00974025   United States;